Fundz

Lycia Therapeutics reported raising $107 Million in an initial SEC Form D filing, from an offering of $107 Million

PUBLIC · LYCAMay 23, 2024

Amount Raised

$107 Million

$107 Million sold, per SEC Form D (first sale Apr 26, 2024)

Round Type

Venture

South San FranciscoBiotechnology

Who to call at Lycia Therapeutics, Inc., and when

A new round usually means Lycia Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Lycia Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Lycia Therapeutics, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Lycia Therapeutics, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Lycia Therapeutics, Inc.

Location

400 East Jamie Court, Suite 200

South San Francisco, California, United States

About

Lycia is a Series B biotech company building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes in circulation and depleting antibodies to specific antigens of interest. The platform can potentially deliver next-generation therapeutics to address a range of difficult-to-treat diseases, including cancer and autoimmune diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Lycia Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsChin L., Chief Medical Officer hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Lycia Therapeutics, Inc.'s next move

See what Strategic adds

Lycia Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.